Virupos 3% ophthalmic ointment 4.5 g

The instruction for medical use of VIRUPOS medicine the Trade name of the drug Virupos Mezhdunarodnoye the unlicensed name Acyclovir Dosage Form oculentum of 3%, 4.5 g contains Structure of 1 g of ointment: active agent – acyclovir of 30 mg, excipient – vaseline white. The description Uniform ointment from white till gray-white color. Pharmacotherapeutic group the Drugs used in ophthalmology. Antiviral means. Acyclovir. The ATX S01AD03 code the Pharmacological Pharmacokinetics Later properties of use of the oculentum containing 3% of acyclovir about 7.5 µmol/l of active agent were found in watery moisture. This concentration many times over exceeds the concentration necessary for achievement of anti-virus action in relation to a herpes simplex virus. Thus, by means of oculentums of acyclovir it is possible to treat not only the superficial, but also intraocular infections caused by a herpes simplex virus. After a course of treatment using the oculentum containing acyclovir (5 drawings a day for 14 days), active ingredient in blood plasma it was revealed not. The pharmacodynamics Acyclovir gets mainly into the cells infected with a virus of a herpes simplex (herpes simplex) or chicken pox (varicella zoster) in pharmacological inactive look then it is phosphorylated to active derivative acyclovir of triphosphate. Then acyclovir triphosphate is built in virus DNA instead of a deoxyguanosine triphosphate with the participation of a virus polymerase and blocks process of accession of other nucleotides to virus DNA. Thus, the chain of DNA collapses, and replication of a virus stops. Indications - the keratitis caused by a virus of a herpes simplex (herpes simplex) the Route of administration and doses bring the Strip of oculentum about 1 cm long in the lower part of a conjunctival sac of 5 times a day every 4 hour. After drawing it is necessary to close eyelids and to rotate eyes in order that ointment was distributed on the surface of an eye. After healing of a keratitis the treatment should be continued for not less than 3 days. When drawing it is necessary to avoid contact of a tip of a tuba with an eye or face skin. Side effects For classification of side effects are used the following determination of frequency: very often (≥1/10), it is frequent (from ≥1/100 to & lt, 1/10), infrequently (≥1/1000 to & lt, 1/100), is rare (≥1/10000 to & lt, 1/1000), is very rare (& lt, 1/10000). - very often: a superficial dot keratopathy which does not demand the termination of treatment and disappears without consequences - often: the passing feeling of easy burning of an eye which is observed at once after drawing, conjunctivitis - is rare: blepharitis - it is very rare: reactions of immediate hypersensitivity, including a Quincke's disease and a small tortoiseshell of the Contraindication - hypersensitivity to acyclovir, a valatsiklovir or auxiliary components of drug Medicinal interactions of Clinically significant interactions it was not established. At simultaneous use with other ophthalmologic drugs it is necessary to maintain a 15-minute interval between drawings. Special instructions of Patients should be informed that after drawing the passing feeling of easy burning can be observed. During drug treatment it is not necessary to carry contact lenses. Pregnancy and the period of a lactation Use of drug during pregnancy is possible when the potential advantage of treatment of mother exceeds possible risk for a fruit. The limited data obtained at the person show that after system introduction drug gets to breast milk. However, after acyclovir oculentum use by mother the dose received by the child who is on breastfeeding will be insignificant. Influence on ability to run the vehicle or potentially dangerous mechanisms Thanks to fat consistence of drug after its drawing can temporarily worsen sight and increase reaction time. It needs to be considered during driving or work with mechanisms and also in the conditions demanding balancing. The overdose At accidental intake of all contents of a tuba containing 135 mg of acyclovir, development of undesirable effects is not expected. A form of release and packing On 4.5 g of oculentum in the aluminum tuba with internal protective varnish coating equipped with a tip and a cap (polyethylene). On 1 tuba together with the instruction for use in the state and Russian languages place in a cardboard box. To Store storage conditions at a temperature not above 25 °C. To store out of children's reach! 3 years not to apply a period of storage after the termination of the expiration date specified on packing. A period of storage after the first opening of packing – 1 month. Prescription status According to the prescription of URSAPHARM Arzneimittel GmbH Industriyestrasse 35, 66129 Saarbruecken, Germany (Industriestrasse 35, 66129 Saarbrucken, Germany) the Owner of the registration certificate: URSAFARM Artsnaymittel GmbH, Saarbruecken, Germany (URSAPHARM Arzneimittel GmbH, Saarbrucken, Germany) the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods): Representative office of LLC Sona-Pharm in Almaty, RK Almaty, Gogol St. 77/85, office 68